Common stock
- Symbol
- LQDA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 30, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release regarding the litigation filed by United Therapeutics Corporation in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder.…
Press release in this filing
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent →Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved in 2025 for the treatment of PAH. YUTREPIA is currently under development for other indications, including SSc-RP and PH-COPD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. To learn more about Liquidia, please visit www.liquidia.com.
Current securities
Registered securities in this filing
LIQUIDIA CORPORATION · 8-K · Filed 2026-09-30
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 30, 2026, Liquidia Corporation, a
Delaware corporation (the “Company”), issued a press release regarding the litigation filed by United Therapeutics Corporation
in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 and the Company’s
lead product, YUTREPIA® (treprostinil) inhalation powder. A copy of the press release
is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.
Filed exhibits (1)
Exhibit 99.1 Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., September 30, 2026 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (‘327 patent) and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder. Today, the Court ruled that claims 1 and 14 of the ‘327 patent, which generally cover the treatment of pulmonary hypertension with interstitial lung disease (PH-ILD) patients with inhaled treprostinil, including dry powder formulations of inhaled treprostinil, are valid and infringed by Liquidia. The remaining claims of the ‘327…
Open exhibit ↗